HC Wainwright Brokers Decrease Earnings Estimates for YMAB

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.23) per share for the quarter, down from their prior forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.23) EPS.

Other analysts also recently issued reports about the company. Oppenheimer reduced their target price on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, May 14th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Truist Financial reduced their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Finally, Bank of America downgraded shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.60.

Y-mAbs Therapeutics Trading Up 1.4%

NASDAQ:YMAB opened at $4.23 on Wednesday. Y-mAbs Therapeutics has a 12 month low of $3.55 and a 12 month high of $16.11. The stock has a market capitalization of $191.55 million, a price-to-earnings ratio of -7.83 and a beta of 0.53. The firm has a fifty day simple moving average of $4.44 and a two-hundred day simple moving average of $6.91.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $20.90 million for the quarter, compared to analysts’ expectations of $19.97 million.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of YMAB. JPMorgan Chase & Co. boosted its holdings in shares of Y-mAbs Therapeutics by 10.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the last quarter. SG Americas Securities LLC raised its position in Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after acquiring an additional 4,163 shares during the period. Principal Financial Group Inc. lifted its stake in Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after purchasing an additional 1,903 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Y-mAbs Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock valued at $2,228,000 after buying an additional 4,963 shares during the last quarter. Finally, AlphaQuest LLC boosted its position in Y-mAbs Therapeutics by 6,911.6% during the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company’s stock worth $212,000 after purchasing an additional 26,748 shares during the period. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.